TABLE 3.
Parameters estimates and uncertainty of the final transaminase levels model
| Submodel | Parameters (unit) | Value (RSE%) | IIV %CV (RSE%) | Correlation IIV % (RSE%) |
|---|---|---|---|---|
| Baseline | TRANS0,ALT (IU/L) | 18.4 (3.35) | 44.4 (3.96) | 57.6 (5.82) |
| TRANS0,AST (IU/L) | 22.6 (2.12) | 29.1 (4.17) | ||
| Effect of the background TB treatment | BGtreat,ALT (%) | −16.1 (18.2) | ||
| BGtreat,AST (%) | 12.4 (13.9) | |||
| Time effect | Tmax,AST (%) | 14.8 (11.0) | ||
| T50,AST (weeks) | 3.92 (34.6) | |||
| Residual error model | Proportional RUVALT (%CV) | 32.6 (2.28) | 31.3 (6.28) | 85.4 (6.05) |
| Proportional RUVAST (%CV) | 20.7 (2.65) | 38.1 (5.38) | ||
| Correlation RUVALT − RUVAST (%) | 65.6 (2.69) |
The %CV is reported as the square root of the variance. RSE of IIV and RUV is reported on the approximate standard deviation scale (standard error/variance estimate)/2.
Abbreviations: φ12, φ24, A12, and A24 represent the acrophases (in h) and amplitudes (in ms) of the 12‐h and 24‐h circadian rhythm cycles; %CV, percent coefficient of variation; %RSE, percent relative standard error; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BGtreat, background TB treatment regimen; IIV, interindividual variability; RUV, residual unexplained variability; T50, time needed to achieve 50% of the maximal effect; TB, tuberculosis; Tmax, maximal time effect; TRANS0, transaminase levels at baseline.